UPClytics
Overview · Filed: Mar 19, 2024

UPC_CFI_123/2024

TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS BY AN INHIBITOR OF COMPLEMENT

Provisional measuresProvisional MeasuresHamburg LDProvisional measuresCase Closed
  • 2024-06-26PI deniedpi_motionApplication for provisional measures

    The Hamburg Local Division dismissed Alexion Pharmaceuticals' application for a preliminary injunction against Samsung Bioepis based on EP 3 167 888, finding that while direct infringement could be established, the court could not be sufficiently certain of the patent's validity given the EPO Technical Board of Appeal's history of rejecting correction requests for SEQ ID NO:4, and thus denied the measure.